Reading Tip!
>To get to the fulltext easy, use the library proxy bookmarklet or activate our Pubmed url for the Get it! button!
Categories
- Acta Derm Venereol (8)
- Allergy (2)
- Am J Dermatopathol (1)
- Am J Kidney Dis (1)
- Anal Bioanal Chem (1)
- Anal Chem (1)
- Ann Med (1)
- Arch Dermatol (3)
- Arch Phys Med Rehabil (1)
- Arthritis Res Ther (1)
- Arthritis Rheum (1)
- Australas J Dermatol (1)
- BMC Proc (1)
- Br J Dermatol (50)
- Cell Tissue Res (1)
- Clin Exp Dermatol (2)
- Contact Dermatitis (51)
- Dermatol Clin (3)
- Dermatol Res Pract (1)
- Dermatol Surg (1)
- Disabil Rehabil (1)
- Discov Med (2)
- Drugs Aging (2)
- Eur J Dermatol (10)
- Eur J Immunol (1)
- Exp Dermatol (4)
- Front Immunol (1)
- Genes Immun (1)
- Genet Test Mol Biomarkers (1)
- Hum Mol Genet (1)
- Hum Mutat (1)
- Hum Pathol (1)
- Infect Immun (1)
- Inflamm Bowel Dis (1)
- Int J Dermatol (1)
- Int J Med Microbiol (1)
- Invest Ophthalmol Vis Sci (1)
- J Allergy Clin Immunol (3)
- J Am Acad Dermatol (10)
- J Clin Invest (1)
- J Clin Virol (1)
- J Cutan Pathol (3)
- J Dermatol Sci (2)
- J Dtsch Dermatol Ges (4)
- J Eur Acad Dermatol Venereol (9)
- J Hand Ther (1)
- J Immunol (1)
- J Invest Dermatol (20)
- J Med Genet (1)
- J Strength Cond Res (2)
- JAMA Dermatol (4)
- JNMA J Nepal Med Assoc (1)
- Lab Chip (1)
- Methods Mol Biol (1)
- Mol Vis (1)
- N Engl J Med (1)
- Ned Tijdschr Geneeskd (13)
- Ned Tijdschr Tandheelkd (1)
- Neth J Med (1)
- Occup Environ Med (1)
- Opt Lett (1)
- PLoS One (2)
- Qual Health Res (1)
- Regul Toxicol Pharmacol (2)
- Report (1)
- Sci Transl Med (1)
- Skin Res Technol (2)
- Trials (1)
Archives
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- December 2019
- October 2019
- September 2019
- July 2019
- May 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- August 2018
- April 2018
- February 2018
- January 2018
- July 2017
- June 2017
- March 2017
- February 2017
- August 2016
- July 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- April 2014
- March 2014
- February 2014
- November 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- August 2012
- July 2012
- June 2012
Contributors
Meta
Monthly Archives: May 2022
Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study
BACKGROUND: Perinatal arterial ischaemic stroke (PAIS) is an important cause of neurodevelopmental disabilities. In this first-in-human study, we aimed to assess the feasibility and safety of intranasally delivered bone marrow-derived allogeneic mesenchymal stromal cells (MSCs) to treat PAIS in neonates. Continue reading
Comments Off on Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study
Dupilumab in a child with severe atopic dermatitis and severe asthma-a rare case with severe limbitis and exercise-induced anaphylaxis
No abstract Continue reading
Comments Off on Dupilumab in a child with severe atopic dermatitis and severe asthma-a rare case with severe limbitis and exercise-induced anaphylaxis
Efficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: results from a prematurely discontinued randomized controlled trial
No abstract Continue reading
Comments Off on Efficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: results from a prematurely discontinued randomized controlled trial
Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study
BACKGROUND: Perinatal arterial ischaemic stroke (PAIS) is an important cause of neurodevelopmental disabilities. In this first-in-human study, we aimed to assess the feasibility and safety of intranasally delivered bone marrow-derived allogeneic mesenchymal stromal cells (MSCs) to treat PAIS in neonates. Continue reading
Comments Off on Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study
Dupilumab in a child with severe atopic dermatitis and severe asthma-a rare case with severe limbitis and exercise-induced anaphylaxis
No abstract Continue reading
Comments Off on Dupilumab in a child with severe atopic dermatitis and severe asthma-a rare case with severe limbitis and exercise-induced anaphylaxis
Efficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: results from a prematurely discontinued randomized controlled trial
No abstract Continue reading
Comments Off on Efficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: results from a prematurely discontinued randomized controlled trial
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
BACKGROUND: Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough infections in vaccinated patients with immune-mediated inflammatory diseases treated with immunosuppressants, but clinical data on breakthrough infections are still scarce. The primary objective of this study was to compare the incidence and severity of SARS-CoV-2 breakthrough infections between patients with immune-mediated inflammatory diseases using immunosuppressants, and controls (patients with… Continue reading
Comments Off on Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
BACKGROUND: Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough infections in vaccinated patients with immune-mediated inflammatory diseases treated with immunosuppressants, but clinical data on breakthrough infections are still scarce. The primary objective of this study was to compare the incidence and severity of SARS-CoV-2 breakthrough infections between patients with immune-mediated inflammatory diseases using immunosuppressants, and controls (patients with… Continue reading
Comments Off on Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial
CONCLUSIONS AND RELEVANCE: Results of this nonrandomized controlled trial suggest that nomacopan can be well tolerated in older patients with bullous pemphigoid and may have therapeutic benefits for suppressing acute flares of this disease. A larger, placebo-controlled randomized clinical trial is warranted to confirm this safety profile and to establish nomacopan as a new therapeutic option for bullous pemphigoid. Continue reading
Comments Off on Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial
Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial
CONCLUSIONS AND RELEVANCE: Results of this nonrandomized controlled trial suggest that nomacopan can be well tolerated in older patients with bullous pemphigoid and may have therapeutic benefits for suppressing acute flares of this disease. A larger, placebo-controlled randomized clinical trial is warranted to confirm this safety profile and to establish nomacopan as a new therapeutic option for bullous pemphigoid. Continue reading
Comments Off on Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial
The importance of accurate epidemiological data of epidermolysis bullosa
No abstract Continue reading
Comments Off on The importance of accurate epidemiological data of epidermolysis bullosa
The importance of accurate epidemiological data of epidermolysis bullosa
No abstract Continue reading
Comments Off on The importance of accurate epidemiological data of epidermolysis bullosa
External validation of prognostic models predicting outcome after chronic subdural hematoma
CONCLUSIONS: None of the examined models showed good predictive performance for outcomes after CSDH treatment in our dataset. This study confirms the difficulty in predicting outcomes after CSDH and emphasizes the heterogeneity of CSDH patients. The importance of developing high-quality models by using unified predictors and relevant outcome measures and appropriate modeling strategies is warranted. Continue reading
Comments Off on External validation of prognostic models predicting outcome after chronic subdural hematoma
Persistent low complement levels and increased interferon gene expression are predictive for disease progression in patients with incomplete systemic lupus erythematosus
No abstract Continue reading
Comments Off on Persistent low complement levels and increased interferon gene expression are predictive for disease progression in patients with incomplete systemic lupus erythematosus
External validation of prognostic models predicting outcome after chronic subdural hematoma
CONCLUSIONS: None of the examined models showed good predictive performance for outcomes after CSDH treatment in our dataset. This study confirms the difficulty in predicting outcomes after CSDH and emphasizes the heterogeneity of CSDH patients. The importance of developing high-quality models by using unified predictors and relevant outcome measures and appropriate modeling strategies is warranted. Continue reading
Comments Off on External validation of prognostic models predicting outcome after chronic subdural hematoma